Nolvadex-Tamoxifen Citrate is oral anti-oestrogen, and the worlds largest selling breast cancer treatment. In 1998, the Food and Drug Administration (FDA) approved Nolvadex-Tamoxifen Citrate for diminishing the occurrence of breast cancer in women who is at high risk of developing the disease. With Nolvadex-Tamoxifen Citrate, it is achievable to reverse a subsisting growth process of dead tissue and stop further growth.
Source: http://articlewisdom.com
No comments:
Post a Comment